Skip to main content

Present and future of immunotherapy in melanoma

By 15 Dicembre 2017Aprile 7th, 2021No Comments

First line choice in melanoma: immunotherapy or target therapy? We asked Omid Hamid, Director of Melanoma Therapeutics of The Angeles Clinic and Research Institute of Santa Monica. And what about monotherapy? In which patients we could use this therapeutical approach? From the Immunotherapy & Melanoma Bridge 2017 held in Naples.